Lexicon Pharma shares plummet after FDA denies appeal against drug rejection

The U.S. FDA denied Lexicon Pharmaceuticals Inc's appeal against the rejection of its add-on treatment for type 1 diabetes, marking the company's third major setback this year and sending its shares plunging 18% on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Spouses Nan and Rex Vint in Indiana both live with type 1 diabetes, and have their own lingo and tactics for keeping their technology straight.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
One of the more unexpected recent findings relating to cellular senescence is that it appears to be an important part of the mechanisms that lead to loss of the pancreatic β-cells responsible for insulin secretion in both type 1 diabetes and type 2 diabetes - which are very different conditions, despite the shared name. The authors of the brief open access commentary noted here discuss the present state of this research. Age is one of the major risk factors for the development of type 2 diabetes mellitus (T2D). However, the understanding of how cellular aging contributes to diabetes pathogenesis is incomplete...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
CONCLUSIONS: T1DM girls revealed a decreased ratio of cortical bone area/muscle area, reflecting disturbed adaptation of the cortical shaft to the muscle force. When the Z-scores of cortical shell dimensions were investigated, cases in Tanner stage 5 diverged from "less mature" individuals, which may suggests that bone shaft development in these individuals was impaired, affecting both size and strength. PMID: 31789294 [PubMed - in process]
Source: Journal of Musculoskeletal Neuronal Interactions - Category: Neurology Tags: J Musculoskelet Neuronal Interact Source Type: research
The Miami-based Diabetes Research Institute focused on finding a cure for type 1 diabetes has been supported by BioRep Technologies for 25 years.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
Background: Fasting during Ramadan is a form of intermittent fasting in which a person abstains from oral intake between the hours of sunrise and sunset. The fasting month of Ramadan is observed by Muslims worldwide. People with type 1 diabetes (T1DM) who choose to fast during Ramadan are at a particularly high risk of acute diabetes complications including hypoglycemia and significant hyperglycemia. We hypothesized that people with uncomplicated T1DM would be able to fast safely during Ramadan following structured education and with daily advanced glucose monitoring.Methods: People with stable and uncomplicated T1DM treat...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Ashley E. Ciecko, Bardees Foda, Jennifer Y. Barr, Sheela Ramanathan, Mark A. Atkinson, David V. Serreze, Aron M. Geurts, Scott M. Lieberman, Yi-Guang ChenSummaryHuman genetic studies implicate interleukin-27 (IL-27) in the pathogenesis of type 1 diabetes (T1D), but the underlying mechanisms remain largely unexplored. To further define the role of IL-27 in T1D, we generated non-obese diabetic (NOD) mice deficient in IL-27 or IL-27Rα. In contrast to wild-type NOD mice, both NOD.Il27−/− and NOD.Il27ra−/− strains ...
Source: Cell Reports - Category: Cytology Source Type: research
CONCLUSION: JIA appears to be associated with an increased risk of T1D compared to asthma and healthy children. PMID: 31787600 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Condition:   Diabetes Mellitus, Type 1 Intervention:   Sponsor:   Tampere University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The company now wants to accelerate the commercial rollout of a system  for management of Type 1 diabetes.
Source: mobihealthnews - Category: Information Technology Source Type: news
Funding Opportunity RFA-DK-19-036 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of clinical trials designed to test the clinical safety and efficacy of artificial pancreas (AP) device systems with the objective of improving glycemic control, reducing acute complications and improving quality of life in people with difficult to control T1D when using standard of care therapies.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
More News: Diabetes | Diabetes Type 1 | Endocrinology | Health | Pharmaceuticals